Abstract 166P
Background
An estimated 841,000 new Hepatocellular Carcinoma (HCC) cases have been identified globally, with Asia having the highest incidence (73%). However, there is limited real world data on how HCC is diagnosed and on the preferred treatment modalities. This study aims to evaluate and compare the presentation and management patterns in patients with HCC across Hong Kong (HK), Singapore (SG) and Thailand (TH).
Methods
Primary research was conducted amongst key HCC therapeutic area experts within Asia Pacific. A total of 18 oncologists, hepatologists and gastrointestinal specialists (6 HK; 6 SG; 6 TH) participated in the qualitative phase and a total of 55 (15 HK; 20 SG; 20 TH) in the quantitative phase. Face-to-face interviews using a discussion guide (Qualitative phase) were conducted in August to October 2019 and structured questionnaires (Quantitative phase) were implemented in October to November 2019. We are presenting the descriptive statistics of the stage at diagnosis, comorbidities and treatment modalities of HCC patients based upon this study.
Results
The key therapeutic area experts reported that patients in Hong Kong and Singapore present at an advanced stage per the Barcelona Clinic Liver Cancer (BCLC) guidelines (Stage C: 76% HK; 63% SG; 45% TH) as compared to patients in Thailand. Cirrhosis was a key etiology in Singapore and Thailand (90%, 77%) and Hepatitis B in Hong Kong (89%). Targeted therapy was the preferred first-line HCC treatment in Hong Kong, Singapore and Thailand (89%, 84%, 88%). Immunotherapy was the preferred second-line HCC treatment in Hong Kong (64%). Chemotherapy was used first-line in Thailand (13%) and second-line in Hong Kong, Singapore and Thailand (3%, 11%, 24%).
Conclusions
The treatment patterns and presentation of HCC patients at diagnosis varies considerably across Hong Kong, Singapore and Thailand. These findings on real world practice will be useful to clinicians in understanding the trends and patterns in the diagnosis of HCC and developing treatment strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kantar.
Funding
IPSEN Pharmaceutical company.
Disclosure
P.K.H. Chow: Advisory/Consultancy: Sirtex Medical; Advisory/Consultancy: Ipsen; Advisory/Consultancy: Oncosil; Advisory/Consultancy: Bristol-Myers Squibb; Advisory/Consultancy: MSD; Advisory/Consultancy: Roche. J-F. Baladi, Y. Chia, B. Ramaswamy: Full/Part-time employment: Ipsen. V. Grillo, A. Acorda, K. Xu, S. Singh, Y. Chen, Y. Gilliam, R. Gowindah: Full/Part-time employment: Kantar.
Resources from the same session
194P - Nab-paclitaxel plus capecitabine as first-line treatment for patients with recurrence or metastatic biliary tract cancer
Presenter: Jun Zhou
Session: e-Poster Display Session
370P - Bespoke circulating tumour DNA assay for the detection of minimal residual disease in esophageal adenocarcinoma patients
Presenter: Emma Ococks
Session: e-Poster Display Session
390P - A real-world clinical study of camrelizumab in the treatment of esophageal cancer
Presenter: Guoping Sun
Session: e-Poster Display Session
203P - Characterization of renal cell carcinoma (RCC) with VHL mutation
Presenter: Yanrui Zhang
Session: e-Poster Display Session
204P - Prospective observational study on pazopanib in patients treated for advanced or metastatic renal cell carcinoma (RCC) in Asia, North Africa and Middle East countries: Final analysis of PARACHUTE study
Presenter: Ravindran Kanesvaran
Session: e-Poster Display Session
205P - A study on organ preservation in muscle invasive urinary bladder cancer patients with intensity modulated radiotherapy and concurrent single agent cisplatin in south Indian population
Presenter: Himani Manchala
Session: e-Poster Display Session
206P - Mutational signature in urothelial carcinoma with TP53 mutation
Presenter: Huan Liu
Session: e-Poster Display Session
207P - Concordance of genomic alterations by next-generation sequencing in tumour tissue versus circulating tumour DNA in urothelial carcinoma
Presenter: wang Wang
Session: e-Poster Display Session
208P - Prognostic factors and outcomes of non-seminomatous germ cell tumours of testis: Experience from a tertiary cancer centre in India
Presenter: Lekha Nair
Session: e-Poster Display Session
210P - Prognostic value of sarcopenia in metastatic renal cell carcinoma patients: A systematic review
Presenter: Angeline Tancherla
Session: e-Poster Display Session